Cydy stock forecast analyst consensus in CYDY stock

Analyst consensus in CYDY stock forecast commentary points to “Hold” ratings for now, awaiting trial results that could either spark rerating or downside revisions. In the reported quarter, new vehicle revenues were down 1% year over year to $3.2 billion but topped our estimate of $3.08 billion due to higher-than-expected sales volume and average selling price (ASP). New vehicle retail units sold totaled 62,890 units (up 2% year over year), beating our projection of 61,831 units. The ASP per new vehicle unit retailed was $50,207 (down 1.9% year over year), beating our estimate of $49,781. Gross profit from the segment came in at $176.7 million, declining 29.1% year over year but topping our estimate of $165 million. Retail used-vehicle revenues contracted 15.1% from the year-ago quarter’s figure to $1.7 billion and missed our projection of $1.87 billion due to lower-than-expected sales volume and ASP. Used vehicle retail units sold totaled 64,071 units (down 9.8% year over year), missing our projection of 67,417 units. ASP per used vehicle unit retailed came in at $26,369 (down 5.9% year over year) and lagged our projection of $27,677. Gross profit from the segment came in at $103.8 million, which fell 16.8% but beat our projection of $103 million. Revenues from wholesale used vehicles were up 7.4% to $151.9 million and surpassed our estimate of $146 million. Gross profit rose from $1.4 million to $6.4 million and topped our estimate of $1.7 million. Net revenues in the finance and insurance business amounted to $328.7 million, which decreased 9.9% from the year-ago quarter and missed our projection of $406.3 million. Gross profit was $328.7 million, which decreased 9.9% and missed our estimate of $406.3 million. Revenues from the parts and service business rose 2.6% to $1.15 billion but missed our estimate of $1.28 billion. Gross profit from this segment came in at $550.6 million, which rose 3.3% year over year but missed our estimate of $600.7 million. Leronlimab is a monoclonal antibody therapy that has potential in several medical conditions including several forms of cancer, HIV, and also COVID-19. Previously, short-seller Citron Research accused CytoDyn of hyping leronlimab, but later withdrew the report. CYDY stock forecast sentiment on retail investor forums shows a bullish tilt, particularly among momentum traders watching insider transaction patterns.